<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439409</url>
  </required_header>
  <id_info>
    <org_study_id>19CH103</org_study_id>
    <secondary_id>2019-A01343-54</secondary_id>
    <nct_id>NCT04439409</nct_id>
  </id_info>
  <brief_title>Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).</brief_title>
  <acronym>AVASNA</acronym>
  <official_title>AVASNA : Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cluster Headache (CH) is associated with ipsilateral vegetative signs, related to
      parasympathetic system hyperactivity and/or signs of sympathetic hypoactivity. The precise
      mechanism of Cluster Headache (CH) is still unknown. The question is whether these
      dysautonomic disorders are simply secondary to the Cluster Headache (CH) process or whether
      they are the triggering factor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study cares about the evolution of the Autonomic Nervous System (ANS) in Cluster
      Headache (CH) seizures. Patients will be offered Holter ECG to study the temporal
      relationships between changes in Autonomic Nervous System (ANS) activity during Headache (CH)
      seizures and changes in Autonomic Nervous System (ANS) activity before and after seizure
      treatment, using heart rate variability measurement.

      The hypothesis is that there would be an initial temporary sympathetic activation, followed
      quickly by parasympathetic hyperactivation and a return to a state of equilibrium.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first night seizure during the basal period, pre-seizure, seizure and after the seizure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of the Low Frequency/High Frequency (LF/HF) ratio at the onset of the first daytime seizure during the basal period, pre-seizure, seizure and after the seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Frequency during daytime and night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of measure of Low Frequency during daytime and night seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Frequency (HF) during daytime and night seizure</measure>
    <time_frame>Day: 7</time_frame>
    <description>Comparison of measure of High Frequency (HF) during daytime and night seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between several parameters</measure>
    <time_frame>Day: 7</time_frame>
    <description>Correlation between Heart Rate Variability (HRV), changes in the Low Frequency/High Frequency (LF/HF) ratio, the Low Frequency (LF) and the High Frequency (HF), and the intensity of pain measured on the Visual Analog Scale (VAS).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Patients with Cluster Headache (CH)</arm_group_label>
    <description>Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter electrocardiogram</intervention_name>
    <description>Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.</description>
    <arm_group_label>Patients with Cluster Headache (CH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Cluster Headache (CH) will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years of age

          -  Affiliated or entitled to a Social Security scheme

          -  Resident in the territories of the hospital grouping of Loire territory (located less
             than 50 km away)

          -  Whose diagnosis of episodic or chronic Cluster Headache (CH) has been confirmed
             according to International Classification of Headache Disorders (ICHD)- 3 criteria

          -  With a regular sinus rhythm and heart rate

        Exclusion Criteria:

          -  Conditions contraindicating the use of injectable sumatriptan

          -  Conditions likely to affect the Autonomic Nervous System (ANS): dysautonomic sensory
             neuropathies, sleep apnea syndrome, etc.

          -  Cognitive or language disorders that may interfere with pain assessment and seizure
             follow-up.

          -  Patients taking treatments that may modify the Autonomic Nervous System (ANS):
             catecholamine (adrenaline, noradrenaline, dopamine), B-stimulants (isoprenaline,
             dobutamine, dopexamine, salbutamol, terbutaline, fenoterol, orciprenaline,
             clenbuterol, salmeterol, formoterol), B-blockers, alpha-stimulants (midodrine,
             alpha-methyl-dopa, clonidine, rilmenidine, moxonidine), alpha-blockers (phentolamine,
             prazosin, urapidil), amphetamine, tyramine, ephedrine, selegiline, cocaine,
             imipramine.

          -  Impossibility to submit to the medical follow-up of the program for geographical,
             social or psychological reasons.

          -  Patient deprived of liberty or under guardianship.

          -  Patient with preventive background treatment of Cluster Headache (CH).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle CREAC'H, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christelle CREAC'H, MD</last_name>
    <phone>(0)4.77.12.76.48</phone>
    <phone_ext>+33</phone_ext>
    <email>christelle.creach@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fleur PETIT, CRA</last_name>
    <phone>(0)4.77.82.95.58</phone>
    <phone_ext>+33</phone_ext>
    <email>Fleur.Petit@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christelle CREAC'H, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland PEYRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malou NAVEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice LIETAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Claude BARTHELEMY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric ROCHE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David CHARIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cluster Headache</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>Seizure</keyword>
  <keyword>Holter</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>(LF/HF) ratio</keyword>
  <keyword>Daytime seizure</keyword>
  <keyword>Night seizure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

